TLDR Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
The document reviewed the role of tyrosine kinases in autoimmune and inflammatory skin diseases, emphasizing the therapeutic potential of kinase inhibitors. It highlighted the effectiveness of JAK inhibitors, such as tofacitinib and ruxolitinib, in treating conditions like alopecia areata, vitiligo, and psoriasis, showing promising results in hair regrowth and symptom reduction. The review also discussed the role of SYK and other kinases in diseases like bullous pemphigoid, where autoantibodies and cytokines contribute to inflammation and tissue damage. Overall, targeting specific kinases was suggested as a significant advancement in treating these skin conditions.
48 citations,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
196 citations,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
222 citations,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
159 citations,
October 2015 in “Science Advances” Blocking JAK-STAT signaling can lead to hair growth.
701 citations,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
1 citations,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
36 citations,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
1 citations,
December 2023 in “Molecules/Molecules online/Molecules annual” JAK inhibitors show promise for treating various skin diseases.
9 citations,
June 2023 in “Cells” Certain natural and synthetic compounds may help treat inflammatory skin diseases by targeting a specific signaling pathway.
4 citations,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
